Back

Eligibility for lipid-lowering randomised clinical trials and long-term outcomes in real-world contemporary patients with atherosclerotic cardiovascular disease

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Drug therapy (1) Drug therapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Miss Pauline Christine Eleonore Schuitema

University Medical Center Utrecht, Utrecht (Netherlands (The))

7 More presentations in this session

Presentation thumbnail
The association between the response of lipid-lowering agents and monogenic variants of familiar hypercholesteremia in Taiwan
Professor P. Liu (Tainan, TW)
Abstract Slides Video
Presentation thumbnail
Prospective validation of a self-report-based model for coronary artery calcium screening and assessment of treatment gaps in lipid-lowering therapy.
Doctor E. Hagberg (Gothenburg, SE)
Abstract Slides Video
Presentation thumbnail
BW-00112 targeting ANGPTL3 results in prolonged reductions in plasma triglycerides, LDL-C, and remnant-C in Chinese healthy subjects
Ms Y. Li (Shanghai, CN)
Abstract Slides Video
Presentation thumbnail
Icosapent ethyl reduces CVD risk in cardiovascular-kidney-metabolic syndrome: REDUCE-IT CKM
Professor M. Miller (Philadelphia, US)
Abstract Slides Video
Presentation thumbnail
PCSK-9-inhibitor therapy improves endothelial function in patients with coronary artery disease
Doctor A. Bosch (Erlangen, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Drug therapy (1)

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Prevalence of REDUCE-IT trial eligible patients in a coronary disease follow-up program
thumbnail
Congress Presentation
Lipid management in high cardiovascular risk patients without prior myocardial infarction or stroke - preliminary data from the VESALIUS-REAL global burden study
thumbnail
Congress Presentation
Sex-specific guideline target value attainment and prognostic value of low-density lipoprotein cholesterol in tertiary care

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources